Message #39 From:
Stock News Bot Date: January 10, 2007 08:57:00 AM
EVSC News Endovasc Strengthens Management Team by Appointing Chief Financial and Chief Compliance Officer
MONTGOMERY, Texas--(BUSINESS WIRE)--Endovasc, Inc - (OTCBB:EVSC)
a Business Development Company focused on acquiring and investing in
companies engaged in the development of innovative cardiovascular and
metabolic drugs as well as nutraceutical supplements, is pleased to
announce the appointment of Mr. Sam Lindsey as the Company’s
new Chief Financial Officer and Chief Compliance Officer. The
appointment was effective January 5, 2007.
Mr. Lindsey brings over 35 years of experience in both the public and
private accounting sectors, most recently serving as the Controller for
R Construction Inc., a privately held oilfield construction company with
over 100 employees. Prior to this, Mr. Lindsey was the CFO and Treasurer
of Reconversion Technologies, Inc, a publicly traded start-up company.
Mr. Lindsey was also the Managing Partner of Lindsey & Phelps PC, a
medium sized accounting firm where he specialized in auditing,
accounting services, taxation, business consulting, and litigation
support services. Mr. Lindsey graduated from the University of Houston
with a Bachelor of Business Administration degree, majoring in
accounting.
Mr. Lindsey is a District Governor for the Lions Club International and
is a Life Member of the Texas Lions Camp. He is also a Life Member of
the Lions Eyes Bank and the recipient of two Lion of the Year awards,
two 100% Director awards to the Texas Lions Camp, Three Club Extensions
Awards, a Key Member Award, International Presidents Growth Award, and
is a Jack Wiech and Melvin Jones Fellow.
Dr. Diane Dottavio, Chief Executive Officer of Endovasc Inc., commented, “We
are pleased to have retained a financial executive of Sam’s
caliber. His accounting and public company experience will prove to be
extremely valuable. I look forward to working with him and welcome him
to Endovasc.”
About Endovasc, Inc.
Endovasc, Inc is focused on investing in private companies that develop
and commercialize drug candidates in the areas of cardiovascular and
metabolic medicine. Endovasc is organized as a business development
company, and has invested in the following subsidiaries: Liprostin Inc.,
which holds the intellectual property for a liposomal based treatment to
increase circulation and reduce leg pain in patients suffering from
vascular disease; Prostent, Inc., which is developing a stent coating
technology; and Nutraceutical Development Corporation, which has
developed marketed technology to increase muscle mass.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain forward-looking
statements that involve risks and uncertainties that may not be evident
at the time of this release.
